Methods for treating interleukin-6 related diseases

What is this patent about?

’052 is related to the field of pharmaceutical immunology, specifically focusing on the treatment of diseases mediated by the cytokine interleukin-6 (IL-6). The background context involves the management of chronic inflammatory and autoimmune conditions, such as rheumatoid arthritis, where IL-6 signaling drives systemic inflammation and joint destruction. While IL-6 antagonists were known to provide therapeutic benefits, the invention addresses the need for improved efficacy and the mitigation of adverse immune responses during long-term treatment.

The underlying idea behind ’052 is that a synergistic therapeutic effect can be achieved by combining a specific IL-6 receptor antagonist with a metabolic antagonist. The inventive insight lies in the discovery that the co-administration of these agents not only enhances the anti-rheumatic effect beyond what is possible with monotherapy but also serves a critical safety function. Specifically, the addition of an immunosuppressant or the use of a high-dose antibody regimen can significantly reduce or prevent allergic reactions and the formation of anti-drug antibodies that typically limit the utility of biologic therapies.

The claims of ’052 focus on a method for treating rheumatoid arthritis through the combined administration of a humanized PM-1 antibody and methotrexate. The independent claim specifically protects the use of this particular humanized antibody, which targets the IL-6 receptor to block signal transduction, in conjunction with effective doses of methotrexate. This combination is positioned as a solution for patients who have had an inadequate response to standard disease-modifying anti-rheumatic drugs.

In practice, the invention works by simultaneously or sequentially delivering the antibody via intravenous infusion and the methotrexate orally. The antibody, such as the humanized PM-1 variant, binds to both membrane-bound and soluble IL-6 receptors, effectively neutralizing the IL-6 signaling pathway. Meanwhile, the methotrexate acts as a chemical stabilizer for the biologic therapy, suppressing the patient's immune system from recognizing the therapeutic antibody as a foreign protein, thereby maintaining higher drug concentrations in the blood over longer intervals.

This approach differs from prior solutions by moving away from simple monotherapy, which often faced diminishing returns or safety hurdles like infusion reactions. By establishing a specific synergistic protocol between a biologic and a traditional immunosuppressant, the invention achieves deeper clinical responses, measured by ACR improvement criteria, while lowering the incidence of hypersensitivity. This dual-action strategy ensures that the biologic remains effective and safe even after repeated administrations in chronic disease settings.